Drug Trial Radar · NCT07935928
A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
381
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Dec 2029
Study completion Jun 2031
Sponsor
- Lead sponsor
- Novatek PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial uses a study drug (NP-101) alone in some parts of the study or with a recommended treatment for GEP-NEC called Nivo/Ipi (a combination of Nivolumab and Ipilimumab) in other parts of the study and tests it against Placebo (look alike capsules with no active drug) with Nivo/Ipi. The study is divided into three parts. Participants will participate in only one of 3 study parts: Part 1- Dose escalation or Part 2 - Dose selection or Part 3 - Selected dose continuation. The goal of this clinical trial is to learn if NP-101 (the study drug) can help people with poorly differentiated GEP-NEC live longer; the study includes males and females, age 18 and older who agree to join the study and who qualify. The main questions the study seeks to answer: 1. Is the study drug in combination with Nivo/Ipi safe? 2. How does the body process the study drug alone and in combination with Nivo/Ipi? 3. How does the body process the study drug with and without food? 4. Can the study drug plus Nivo/Ipi (the recommended treatment) help people with GEP-NEC live longer than people who do not take the study drug, but who do receive recommended treatment? Participants will be asked to report how they are feeling, allow for blood draws, body scans, visit the clinic for testing, allow for removal of tumor tissue, take study drug or capsules without medication (along with the recommended treatment) and other procedures which will be explained, along with the study visit schedule, in detail by the study staff before agreeing to participate.
Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
Interventions
NP-101Drug
NP-101 is a GMP manufactured enteric capsule containing 600 mg of active pharmaceutical ingredient derived from a botanical source.
PlaceboOther
A GMP manufactured enteric capsule containing corn oil. Closely matched to NP-101 in size, shape, color and viscosity of API.
Ipi/NivoDrug
Non-experimental treatment intervention for GEP-NEC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I Primary Safety ObjectiveTime frame: The DLT evaluation period for each participant is the first 28 days
- Part I Pharmacokinetic ObjectiveTime frame: PK sampling will occur at various timepoints and frequencies for the first 16 weeks.
- Part 2 - Primary Efficacy ObjectiveTime frame: Response will be defined by participant response at 8 weeks.
- Part 2/Part 3 Primary Efficacy ObjectiveTime frame: The maximum participation could be up to the final safety follow-up visit which occurs 90 days after last dose. Assuming survival the maximum time could be up to Study Day 821.
- Part 2/3 Pharmacokinetic ObjectiveTime frame: Participants in Part 2/3 would participate in the PK sampling until the last day of cycle 4 (Each cycle is 28 days) which for Part2/3 would be Study Day 112
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.